Credit: Reuters/Shannon Stapleton
Allergan Chief Executive David Pyott speaks during an interview in New York July 8, 2014.
The offer values Allergan at $219 per share, compared with its Friday close of $198.65. Valeant's latest cash-and-stock offer is currently worth about $54 billion.
(Reporting by Caroline Humer; Additional reporting by Amrutha Penumudi in Bangalore; Editing by Bernadette Baum)
Entities 0 Name: Amrutha Penumudi Count: 1 1 Name: David Pyott Count: 1 2 Name: New York Count: 1 3 Name: Caroline Humer Count: 1 4 Name: Bernadette Baum Count: 1 5 Name: Allergan Count: 1 6 Name: Reuters\/Shannon Stapleton Allergan Count: 1 7 Name: Bangalore Count: 1 Related 0 Url: http://ift.tt/1uAC7Qa Title: UPDATED: Actavis bags top 10 Big Pharma status with $66B Allergan buyout Description: Actavis CEO Brent Saunders It's a done deal. Actavis ($ACT) and Allergan ($AGN) have come to terms on a buyout that values the Botox maker at $66 billion, dwarfing a bid from Valeant and William Ackman that forced the biotech into play.
